Item
Calcium Ascorbate (3179)
Calcium ascorbate is a chemically defined compound having the empirical formula C12H14CaO12 2H2O and
a molecular weight of 426.35.
Nutrient / Vitamin
Attributes
- Gluten-free
- Ingredient declaration
Locations
| Location name | Address |
|---|---|
| CSPC WEISHENG PHARMACEUTICAL | No. 236 Huange Street High-Tech Development Zone Shijiazhuang, HE 50035 CHN |
| Jiangsu Jiangshan Pharmaceutical Co., Ltd. | No. 61, Jiangshan Road Jingjiang, JS 214500 CHN |
Documents
| Type | Location | File name | Effective | Expiration |
|---|---|---|---|---|
| HARPC Food Safety Plan (Item) | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | 3rd party-Haccp doc - Prinova.pdf | 10/19/2022 | 10/18/2025 |
| HACCP | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | 3rd party-Haccp doc - Prinova.pdf | 8/13/2024 | 8/13/2027 |
| Gluten | CSPC WEISHENG PHARMACEUTICAL | Allergen - 2024-02-05T132929.433.pdf | 11/1/2023 | 10/31/2024 |
| Gluten | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergen - 2024-10-21T161255.352.pdf | 6/14/2024 | 6/14/2026 |
| Allergens EU/UK | CSPC WEISHENG PHARMACEUTICAL | Allergens EU/UK.pdf | 6/4/2024 | 6/4/2026 |
| Allergens EU/UK | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergens EU/UK.pdf | 1/6/2025 | 1/6/2027 |
| Allergens | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergens.pdf | 3/18/2024 | 3/18/2026 |
| Allergens | CSPC WEISHENG PHARMACEUTICAL | Allergens.pdf | 7/15/2024 | 7/15/2026 |
| CoA Sample | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Approved COA Template - 2025-01-27T121628.814.pdf | 7/25/2024 | 7/25/2026 |
| CoA Sample | CSPC WEISHENG PHARMACEUTICAL | Approved COA Template 7.pdf | 11/1/2021 | 11/1/2023 |
| WADA/NSF/NFL Statement | CSPC WEISHENG PHARMACEUTICAL | Banned Substance 73.pdf | 11/1/2021 | 11/1/2023 |
| Safety Data Sheet (SDS) | CSPC WEISHENG PHARMACEUTICAL | calcium ascorbate - CSPC Weisheng - SDS 2021 (1).pdf | 6/23/2022 | 6/22/2024 |
| Pesticide | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2023-12-13T152741.815.pdf | 11/1/2022 | 10/31/2024 |
| Melamine | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities (100).pdf | 11/1/2022 | 11/1/2023 |
| Residual Statement | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities (97).pdf | 11/1/2022 | 11/1/2023 |
| Heavy Metal | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities 3.pdf | 11/1/2021 | 11/1/2023 |
| Country of Origin EU/UK | CSPC WEISHENG PHARMACEUTICAL | Country of Origin EU/UK.pdf | 4/25/2022 | 4/24/2025 |
| Country of Origin EU/UK | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Country of Origin EU/UK.pdf | 7/15/2022 | 7/14/2025 |
| Country of Origin | CSPC WEISHENG PHARMACEUTICAL | Country of Origin.pdf | 6/15/2023 | 6/14/2026 |
| Country of Origin | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Country of Origin.pdf | 9/20/2024 | 9/20/2027 |
| Sewage Statement | CSPC WEISHENG PHARMACEUTICAL | CSPC Weisheng - Ascorbic Acid - Organic Compliance (7).pdf | 12/11/2021 | 12/11/2023 |
| Vegan/Vegetarian Statement | CSPC WEISHENG PHARMACEUTICAL | Dietary Status (58).pdf | 12/15/2023 | 12/14/2025 |
| Dietary Supplement Questionnaire | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Dietary Supplement Questionnaire.pdf | 10/25/2019 | 10/24/2020 |
| HACCP Process Flow Diagram | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Dossier_5015848 2.pdf | 3/30/2021 | 3/30/2023 |
| Shelf Life | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Dossier_5015848 6.pdf | 3/30/2021 | 3/29/2024 |
| Safety Data Sheet (SDS) | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | DSM - calcium ascorbate - SDS 2020.pdf | 11/26/2020 | 11/26/2023 |
| GRAS/NDI/ODI Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | FDA Regulatory Status - Calcium Ascorbate.pdf | 9/13/2024 | 9/13/2027 |
| HACCP Process Flow Diagram | CSPC WEISHENG PHARMACEUTICAL | Flow Chart 125.pdf | 1/1/2022 | 1/1/2024 |
| GMO | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | GMO - 2023-07-17T095947.384.pdf | 6/30/2022 | 6/29/2024 |
| GMO | CSPC WEISHENG PHARMACEUTICAL | GMO-Non-GMO Project (25).pdf | 12/14/2022 | 12/13/2024 |
| HACCP | CSPC WEISHENG PHARMACEUTICAL | HACCP Program 7.pdf | 5/14/2021 | 5/13/2024 |
| Halal | CSPC WEISHENG PHARMACEUTICAL | Halal Certificate (157).pdf | 7/28/2022 | 7/27/2026 |
| Item Questionnaire | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Item Questionnaire.pdf | 10/28/2019 | 10/27/2020 |
| Kosher | CSPC WEISHENG PHARMACEUTICAL | Kosher Certificate (210).pdf | 8/9/2022 | 8/31/2023 |
| Kosher | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Kosher Certificate 117.pdf | 12/31/2023 | |
| National Bioengineered Food Disclosure Standard (Simplified) | CSPC WEISHENG PHARMACEUTICAL | National Bioengineered Food Disclosure Standard (Simplified).pdf | 4/25/2022 | 4/24/2025 |
| National Bioengineered Food Disclosure Standard (Simplified) | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | National Bioengineered Food Disclosure Standard (Simplified).pdf | 7/15/2022 | 7/14/2025 |
| Nutrition EU/UK | CSPC WEISHENG PHARMACEUTICAL | Nutrition EU/UK.pdf | 4/25/2022 | 4/24/2025 |
| Nutrition | CSPC WEISHENG PHARMACEUTICAL | Nutrition.pdf | 4/25/2022 | 4/24/2025 |
| Nutrition | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Nutrition.pdf | 2/15/2023 | 2/14/2026 |
| Ingredient Statement | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2023-03-22T111319.179.pdf | 2/22/2023 | 2/22/2024 |
| Ingredient Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet - 2024-01-17T151043.206.pdf | 3/31/2023 | 3/30/2024 |
| California Prop. 65 | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2025-01-27T105626.483.pdf | 10/8/2024 | 10/8/2026 |
| Heavy Metal | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet (109).pdf | 3/31/2022 | 3/30/2024 |
| WADA/NSF/NFL Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet 22.pdf | 3/31/2022 | 3/30/2024 |
| BSE - TSE | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet 27.pdf | 3/31/2022 | 3/30/2025 |
| Vegan/Vegetarian Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet 29.pdf | 3/31/2022 | 3/30/2024 |
| EtO Statement | CSPC WEISHENG PHARMACEUTICAL | Production Process (38).pdf | 11/1/2021 | 10/31/2024 |
| Irradiation Status Statement | CSPC WEISHENG PHARMACEUTICAL | Production Process (64).pdf | 11/1/2022 | 10/31/2024 |
| California Prop. 65 | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Prop 65 76.pdf | 9/13/2020 | 9/13/2022 |
| BSE - TSE | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet (117).pdf | 3/1/2022 | 2/28/2025 |
| Product Specification Sheet | CSPC WEISHENG PHARMACEUTICAL | Specification - Factory (18).pdf | 1/1/2022 | 12/31/2024 |
| Suitability Requirements | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Suitability Requirements.pdf | 10/28/2019 | 10/27/2022 |
| GRAS/NDI/ODI Statement | CSPC WEISHENG PHARMACEUTICAL | US Regulatory Status (20).pdf | 10/25/2022 | 10/25/2025 |
| Product Specification Sheet | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | US SPECIFICATION - 2024-10-21T152902.722.pdf | 4/20/2024 | 4/20/2027 |
